What studies of DHEA found
At a glance, by condition
ME/CFS: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty): 6 of 8 findings are C.
8 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: DHEA might help some people with ME/CFS, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- DHEA · ME/CFS is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
ME/CFS
Symptoms
Anxiety1 study · 23 people took DHEA Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (23 in all).
Studies with no comparison group23 in the study · 6 months · 25 mg/day initially; increased by increments of 25 mg/day to a maximum of 100 mg/day
Anxiety improved.
The evidence is very uncertain about the effect of DHEA on anxiety in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (23 in all)
See the 1 study
-
A pilot study employing Dehydroepiandrosterone (DHEA) in the treatment of chronic fatigue syndrome. (1999)
- People in the study
- 23 in the study
- Dose
- 25 mg/day initially; increased by increments of 25 mg/day to a maximum of 100 mg/day
- Outcome
- anxiety
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Cognition (brain fog)1 study · 23 people took DHEA Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (23 in all).
Studies with no comparison group23 in the study · 6 months · 25 mg/day initially; increased by increments of 25 mg/day to a maximum of 100 mg/day
Cognition (brain fog) improved.
The evidence is very uncertain about the effect of DHEA on cognition (brain fog) in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (23 in all)
See the 1 study
-
A pilot study employing Dehydroepiandrosterone (DHEA) in the treatment of chronic fatigue syndrome. (1999)
- People in the study
- 23 in the study
- Dose
- 25 mg/day initially; increased by increments of 25 mg/day to a maximum of 100 mg/day
- Outcome
- memory
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Fatigue1 study · 23 people took DHEA Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (23 in all).
Studies with no comparison group23 in the study · 6 months · 25 mg/day initially; increased by increments of 25 mg/day to a maximum of 100 mg/day
Fatigue improved.
The evidence is very uncertain about the effect of DHEA on fatigue in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (23 in all)
See the 1 study
-
A pilot study employing Dehydroepiandrosterone (DHEA) in the treatment of chronic fatigue syndrome. (1999)
- People in the study
- 23 in the study
- Dose
- 25 mg/day initially; increased by increments of 25 mg/day to a maximum of 100 mg/day
- Outcome
- fatigue
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Low mood or anxiety1 study · 23 people took DHEA Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (23 in all).
Studies with no comparison group23 in the study · 6 months · 25 mg/day initially; increased by increments of 25 mg/day to a maximum of 100 mg/day
Low mood or anxiety improved.
The evidence is very uncertain about the effect of DHEA on low mood or anxiety in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (23 in all)
See the 1 study
-
A pilot study employing Dehydroepiandrosterone (DHEA) in the treatment of chronic fatigue syndrome. (1999)
- People in the study
- 23 in the study
- Dose
- 25 mg/day initially; increased by increments of 25 mg/day to a maximum of 100 mg/day
- Outcome
- feelings of helplessness
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Pain1 study · 23 people took DHEA Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (23 in all).
Studies with no comparison group23 in the study · 6 months · 25 mg/day initially; increased by increments of 25 mg/day to a maximum of 100 mg/day
Pain improved.
The evidence is very uncertain about the effect of DHEA on pain in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (23 in all)
See the 1 study
-
A pilot study employing Dehydroepiandrosterone (DHEA) in the treatment of chronic fatigue syndrome. (1999)
- People in the study
- 23 in the study
- Dose
- 25 mg/day initially; increased by increments of 25 mg/day to a maximum of 100 mg/day
- Outcome
- Pain severity
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Depression1 study · 23 people took DHEA Little or no difference D
Why this grade: Little or no difference, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (23 in all).
Studies with no comparison group23 in the study · 6 months · 25 mg/day initially; increased by increments of 25 mg/day to a maximum of 100 mg/day
No clear change in depression.
The evidence is very uncertain about the effect of DHEA on depression in ME/CFS. Little or no difference · very low certainty D
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (23 in all)
See the 1 study
-
A pilot study employing Dehydroepiandrosterone (DHEA) in the treatment of chronic fatigue syndrome. (1999)
- People in the study
- 23 in the study
- Dose
- 25 mg/day initially; increased by increments of 25 mg/day to a maximum of 100 mg/day
- Outcome
- depression
- Effect
- no clear difference
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Daily life and health overall
Daily functioning1 study · 23 people took DHEA Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (23 in all).
Studies with no comparison group23 in the study · 6 months · 25 mg/day initially; increased by increments of 25 mg/day to a maximum of 100 mg/day
Daily functioning improved.
The evidence is very uncertain about the effect of DHEA on daily functioning in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (23 in all)
See the 1 study
-
A pilot study employing Dehydroepiandrosterone (DHEA) in the treatment of chronic fatigue syndrome. (1999)
- People in the study
- 23 in the study
- Dose
- 25 mg/day initially; increased by increments of 25 mg/day to a maximum of 100 mg/day
- Outcome
- Satisfaction with the ability to do activities
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Quality of life1 study · 23 people took DHEA Little or no difference D
Why this grade: Little or no difference, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (23 in all).
Studies with no comparison group23 in the study · 6 months · 25 mg/day initially; increased by increments of 25 mg/day to a maximum of 100 mg/day
No clear change in quality of life.
The evidence is very uncertain about the effect of DHEA on quality of life in ME/CFS. Little or no difference · very low certainty D
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (23 in all)
See the 1 study
-
A pilot study employing Dehydroepiandrosterone (DHEA) in the treatment of chronic fatigue syndrome. (1999)
- People in the study
- 23 in the study
- Dose
- 25 mg/day initially; increased by increments of 25 mg/day to a maximum of 100 mg/day
- Outcome
- ability to cope with the illness
- Effect
- no clear difference
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Side effects
Side effects studies reported2 kinds
| Side effect | Studies that reported it |
|---|---|
| Dizziness | 1 study |
| Nausea or stomach upset | 1 study |
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
25 mg at the start
- 2Raise
Raised step by step in 1 of 1 studies
- 3Top dose
Most often 100 mg (1 of 1 studies)
Doses across 1 study
25 to 100 mg.
Each study’s dose, as printed
- 25 mg/day initially; increased by increments of 25 mg/day to a maximum of 100 mg/day A pilot study employing Dehydroepiandrosterone (DHEA) in the treatment of chronic fatigue syndrome. (1999)
All papers
- The value of the dehydroepiandrosterone-annexed vitamin C infusion treatment in the clinical control of chronic fatigue syndrome (CFS). I. A Pilot study of the new vitamin C infusion treatment with a volunteer CFS patient.1996 · compared with another group
Summary
This pilot study followed a single male volunteer with chronic fatigue syndrome (CFS) from August 1995 to May 1996. The paper does not report where the patient was from or how he was selected. An annex-free vitamin C drip infusion set (the old set) and a dehydroepiandrosterone-annexed vitamin C infusion set (the new set) were prepared. The patient also received oral erythromycin and chloramphenico; the abstract does not give doses, schedules or durations for the infusion sets or antibiotics. The report describes the first, second and 3rd stages of disease. From August to October 1995, the old infusion together with short-term antibiotics was found effective for control of pneumonia. From November 1995 to January 1996, signs of pneumonia recurrence became eminent despite moderate frequency of the old treatment and stepwise prolongation of antibiotics. From February to May 1996, alternating the old and new infusions together with long-term antibiotics led to substantial extinction of pneumonia signs (leucocytosis, tachycardia etc). An immunological survey of lymphocyte subsets including NK cell percent failed to find a coherent change. Side effects and withdrawals were not reported. No enrolled or analysed counts, and no comparison-group numbers, are reported. The authors state no limitations in the abstract.
- The value of the dehydroepiandrosterone-annexed vitamin C infusion treatment in the clinical control of chronic fatigue syndrome (CFS). II. Characterization of CFS patients with special reference to their response to a new vitamin C infusion treatment.1996 · compared with another group · 313 in the study
Summary
This clinical study examined vitamin C infusion treatments for chronic fatigue syndrome (CFS). The authors enrolled 313 chronic pneumonia patients in Nagoya, Japan, whose clinical course fit the criteria for CFS. Patients received either the combined use of the old (annex-free) and new (dehydro-epiandrosterone-annexed) vitamin C infusion treatments or the single use of the old vitamin C infusion treatment. The duration of treatment was not reported. The study measured control of CFS. The combined use of the old and new vitamin C infusion treatments was more effective for the control of CFS than the single use of the old vitamin C infusion treatment. No per-group numbers, statistical test, or significance value were reported. For harms, the authors stated that evidence was available to indicate that the sole use of the new vitamin C infusion treatment may induce a state of gonadal steroid excess together with various other problems in the recipient. No counts of side effects or withdrawals were reported for the comparison groups. The authors did not report study limitations.
- The results of a unique dietary supplement (nutraceutical formulation) used to treat the symptoms of long-haul COVID.2022 · no comparison group · 51 in the study
Summary
This one-arm, open-labeled study at a single site enrolled 51 eligible patients from 18 states with long-haul COVID, recruited from the local patient population and through social media advertising. Participants took a nutraceutical formulation as one serving twice a day with food for 4 weeks, with no comparison group. They rated the severity of 12 symptoms and their general wellbeing at baseline, 2- and 4-week time points. The authors report that on average all symptoms were significantly milder after 2 weeks, with further improvement after 4 weeks, and that the decrease in severity of all symptoms was statistically significant at both the 2- and 4-week time points. Each symptom was reported as significantly attenuated in 72 to 84% of participants, 46 out of 51 participants reported more symptoms that improved than worsened, 59% reported a noticeable improvement in general wellbeing, and the general profile improved for 88% of participants. Minor adverse events included three patients with vertigo and one patient each with increased anxiety, a gout attack, increased joint pain and reinfection with COVID; among the remaining five participants, one reported feeling a worsening in general wellbeing. The authors state the study had no placebo.
- A pilot study employing Dehydroepiandrosterone (DHEA) in the treatment of chronic fatigue syndrome.1999 · no comparison group · 23 in the study
Summary
This uncontrolled, prospective, 6-month study asked whether oral DHEA would change symptoms in chronic fatigue syndrome (CFS). The authors selected 23 white women ages 35-55 with DHEA-S <2.0 ug/mL from a database; all received oral micronized DHEA, initially 25 mg/day, with increases by 25 mg/day to a maximum of 100 mg/day if DHEA-S remained low or no clinical response occurred. There was no comparison group. Physical and psychological impairment and disability were measured with the MHAQII before DHEA and at 3-month intervals. Over the trial period, pain severity decreased by 18.0% (p = 0.035) and fatigue improved by 21% (p = 0.009). Satisfaction with the ability to do activities improved by 14% (p = 0.033), ability to cope improved by 6% (ns), and helplessness decreased by 11% (p = 0.015). Depression decreased by 17% (ns), anxiety by 35% (p < 0.01), thinking by 26% (p < 0.01), memory by 17% (p < 0.05), and sexual problems by 22% (p = 0.06). Acne or a reddish papular rash occurred in 6 of 23 patients at 3 months and 4 of 23 at 6 months; GI toxicity occurred in 2 of 23 at 3 months; other side effects in 4 of 23. HDL cholesterol fell by 13% (p = 0.016).
- P05.07. Chronic Fatigue, Depression, and Sleep Disturbances in a 20-year-old Male Collegiate Basketball Player: A Case Report2013 · combination: given with other treatments · 1 in the study
Summary
This conference abstract reports a case report of one 20-year-old male collegiate basketball player with chronic fatigue, depression, and abnormal sleep patterns; he was diagnosed with chronic fatigue syndrome and overtraining syndrome by a specialty physician group. At his initial visit to a chiropractic physician specializing in functional medicine, functional testing reportedly showed adrenal syndrome, Helicobacter pylori, Giardia, Entamoeba histolytica, and Cryptosporidium parvum infections, lead and mercury toxicity, and abnormal amino acid levels on organic cation transporter status. The patient was given recommended specific dosages of DHEA, licorice root, and pregnenlone to reduce adrenal syndrome; botanical antimicrobial and antiparasitic supplementation; additional nutrients and silymarin; and a protocol of 5-HTP and tyrosine. He also changed to an ancestral diet and was recommended a core multivitamin, antioxidant, and essential fatty acid supplementation, with other personalized recommendations based on functional labs. Treatment duration was not reported. There was no comparison group and no randomisation. After treatment, the patient experienced restoration of normal sleep patterns and elimination of his depression and chronic fatigue, and was able to exercise and maintain a normal lifestyle. Harms and withdrawals were not reported. The authors concluded that uncommon patient populations can suffer chronic fatigue secondary to subclinical infections regardless of apparent health status and that functional analysis of adrenal, gastrointestinal, and detoxification organ systems can assist in complex cases. They did not report limitations.
- Impact of nutrition on long COVID.2026 · review
Summary
This narrative review examined nutritional and exercise interventions for long COVID; it did not report its own cohort. It describes a single-site RCT with n = 151 participants; n = 98 received VitK2/D3 and n = 53 received standard of care, and participants who received Vit K2/D3 showed a 7.1% reduction in long COVID symptoms compared to control group. A randomized, double-blind, placebo-controlled trial with n = 80 patients (n = 40 post COVID patients; n = 40 placebo) gave 60 000 IU of Vitamin D weekly for 8 weeks; the vitamin D group showed significant improvements in CFQ, DASS-anxiety and ACE, but no significant changes were found PQSI, DASS depression, TMT, IL-6 or CRP levels; Table 2 entry 11 reported this vitamin D supplementation with very low side effects. A multicentre trial with n = 144 patients (n = 71 vitamin D3 group; n = 71 placebo group) gave a single oral dose of 200 000 IU Vitamin D3 and found no significant differences between Vit D3 and placebo group for listed symptoms and quality of life upto 1 year of follow up. Probiotic mixture VSL#3® reduced fatigue and significantly improved physical functioning and gasterointestinal symptoms. Stopping or worsening was not reported. The review states limitations in trial design.
- Exploring the Potential of Dietary Supplements to Alleviate Pain Due to Long COVID.2025 · review
Summary
This review explored dietary supplements for pain due to long COVID. It was a review, not a randomised trial; it had no comparison group, and the review itself did not report enrollment, setting, or follow-up. It summarized studies in long COVID or post-COVID syndrome, including studies with 60, 33, 69, 1, 463, 39, 51, 80, 53, 20, and 12 participants. Treatments included acetyl-l-carnitine 500 mg/day, palmitoylethanolamide 600 mg twice daily, PEA-LUT 770 mg, SIM01, VSL#3®, a vitamin D–containing supplement, vitamin D, marine oil enriched in SPMs, a multinutrient supplement, NAC plus guanfacine, and metformin. Durations reported in the recorded findings included 2 weeks, 4 weeks, 6 months, and 10 months. Measured outcomes included pain, persistent post-COVID symptoms, smell recovery, fatigue, memory loss, concentration, gastrointestinal upset, general unwellness, cognitive abilities, physical functioning, anxiety, depression, and long COVID risk. Findings included improvements in pain, fatigue, cognitive symptoms, smell, and some quality-of-life domains; one report noted no improvement in anxiety, depression, performance, or somatization. Recorded side effects were minimal side effects with vitamin D and mild adverse events with LDN; another recorded harms statement concerned antidepressants, and 19 participants discontinued because of adverse events (12 gabapentin, 7 placebo). The authors stated that clinical experience in long COVID-associated pain is still limited.
- Treatments for Long COVID autonomic dysfunction: a scoping review.2025 · review
Summary
This scoping review included 11 effectiveness studies, 11 guidelines/position statements, and 15 unpublished/ongoing studies of Long COVID autonomic dysfunction. Among comparative data, an NRCS in Italy gave fexofenadine 180 mg/day plus famotidine 40 mg/day to 14 patients and compared them with 13 who received no antihistamines; follow-up increased heart rate was 29% vs. 85% (p = 0.0063) and abdominal disorders 14% vs. 62%. An RCT of 463 patients compared SIM01 with placebo: fatigue alleviation 63% vs. 43% (OR 2.273, 95% CI 1.520–3.397), GI upset 70% vs. 54% (OR 1.995, 95% CI 1.304 to 3.051); quality of life 76.0 vs. 74.5 (p = 0.17) and physical activity p = 0.37 did not differ significantly. Any AE was 9.5% vs. 10.8%. Single-arm studies reported pre-post changes: maraviroc plus pravastatin (18), SSRIs (95; serious side effects 31.6% [30/95], mild 54.7% [52/95]), a nutraceutical (51), multicomponent treatment with salt/water/compression plus bisoprolol (32), HRV biofeedback (13), inspiratory muscle training (26), and SGB (41; vagal response 7.3% [3/41], transient hoarseness 9.8% [4/41]). Review authors state existing studies are often small and uncontrolled.
- Theory: Treatments for Prolonged ICU Patients May Provide New Therapeutic Avenues for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).2021 · review
Summary
This paper is an overview of treatment trials for prolonged intensive care unit (ICU) patients, related to ME/CFS; it reports no study enrollment or analysis numbers for an own cohort. It discusses trials of peripheral hormones and pituitary secretagogues. In fibromyalgia, Lowe et al. reported "significant improvement in clinical symptoms were recorded in T3 phases compared to baseline and placebo phases" with T3 at 75–150 mcg/day. Teitelbaum et al. reported that euthyroid ME/CFS and fibromyalgia patients given T4 (Synthroid) or naturally desiccated thyroid hormone (Armor Thyroid) "in addition to adrenal hormones, vitamins, minerals, and antibiotics—also experienced significant improvements." In prolonged critical illness, van den Berghe et al. reported that GHRH or GHRP-2 "reactivated the pulsatile secretion of GH by the pituitary, and the plasma concentrations of IGF-1 and IGFBP-3 increased"; TRH reactivated pulsatile TSH and increased T4 and T3; reverse T3 also increased. The paper states that "somewhat higher doses of hydrocortisone (25–35 mg per day) lead to a moderate decrease in endogenous adrenocorticotropic hormone (ACTH) and cortisol production in ME/CFS patients." Harms include "a large-scale double-blind randomized control study of rhGH infusions undertaken in 1999 resulted in increased mortality of critically ill patients." The authors state limitations: "ME/CFS and prolonged critical illness are not identical illnesses."